In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $2.24.
According to TipRanks.com, Roy is a 4-star analyst with an average return of 4.7% and a 31.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Moderate Buy with an average price target of $5.33.
See today’s best-performing stocks on TipRanks >>
Adaptimmune Therapeutics’ market cap is currently $375.5M and has a P/E ratio of -2.13.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADAP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More on ADAP:
